CULVER CITY, Calif.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today reported financial results for its fourth quarter and full year ended December 31, 2017.
In August 2017, NantHealth sold its provider/patient engagement assets to Allscripts to focus on core competencies and accelerate the plan to achieve profitability. As a result, the company has classified the current and prior period operating results of its provider/patient engagement business as discontinued operations. All results presented below represent the company’s continuing operations.
GPS Cancer – Highlights
- Test Growth: The company reported 606 GPS Commercial Tests were ordered in Q4, up from 547 in Q3.
- New National GPS Cancer Payer: In Q1 2018, the company signed a new GPS Cancer reimbursement contract with a large, national healthcare IT company.
- New Lab Services Arrangement: In Q1 2018, the company signed a laboratory services agreement with a 20+ facility hospital system for the availability of GPS Cancer testing to its patient community.
- Expanded International Adoption: In Q1 2018, the company signed a strategic reseller agreement with a partner in the United Kingdom for the provision of molecular analysis services for clinical studies and other research initiatives.
- FDA Submission: In Q1 2018, NantHealth submitted a 510K premarket notification application to the FDA for tumor/normal DNA sequencing.
- Company to Provide GPS Cancer Molecular Analysis to the University of California San Francisco (UCSF) to Support Research Initiative Focused on Metastatic Breast Cancer: This study will allow UCSF researchers to utilize advancements made in molecular technology to examine the potential clinical feasibility of molecular profiling, including gene mutations and gene expression in the context of patient care. The biopsy materials collected will also allow researchers to examine immune markers within the tumor architecture. Results of the clinical study to be presented at major medical conferences.
“We continue to make excellent progress on a number of operational fronts,” said Patrick Soon-Shiong, M.D., Chief Executive Officer and Chairman of NantHealth. “The number of ordered GPS Commercial Tests continued to grow in our fourth quarter from the previous quarter and February 2018 was the largest month of orders in the company’s history. Moreover, we have entered into a number of contracts in the first quarter of 2018, including a reimbursement contract with a new, national GPS Cancer Payer, a laboratory services agreement with a large, multi-facility hospital system and a strategic reseller agreement with a partner in the United Kingdom. We also recently completed the submission of a 510K premarket notification application to the FDA for tumor/normal DNA sequencing.”
Software and Services Highlights:
- In Q4 2017, the company signed a three year NaviNet renewal contract with a total contract value of more than $1.2 million and also went live with one of its largest customers for its new Document Exchange solution.
- In Q1 2018, the company signed another NaviNet renewal contract with a total contract value of approximately $17 million.
- Clinical Decision Support: In Q4 2017, the company signed an expanded services contract with an existing, national insurance carrier customer, with the potential to extend the availability of the Eviti solution to an additional 2.4 million lives.
- In Q4 2017, the company signed a device connectivity license contract extension with an existing customer, with the potential to expand its solution to additional facilities within the customer’s 74 hospital system.
- The company’s pipeline for device connectivity sales continues to progress, with numerous international opportunities developing through its strategic resellers in Europe and Asia.
- The company presented “The Future of Device Connectivity Across the Continuum of Care” at the Healthcare Information & Management Systems Society (HIMSS) Annual Conference & Exhibition 2018.
“We reported a strong fourth quarter with revenues increasing on a reduced cost base. Importantly, our SaaS business continues to grow and generate healthy gross margins,” said Ron Louks, Chief Operating Officer of NantHealth. “We’ve had a remarkable turnaround in our quarterly operating results. We are proud of what our organization has been able to accomplish over the second half of 2017 and look forward to continuing this momentum in 2018.”
Business and Financial Highlights
For the 2017 fourth quarter, total net revenue increased 25% to $22.3 million from $17.8 million in 2016 fourth quarter. Gross profit was $13.4 million, or 60% of total net revenue, compared with $7.0 million, or 39% of total net revenue, for the prior-year fourth quarter. Selling, general and administrative (SG&A) expenses were $20.8 compared with $16.4 million. Research and development (R&D) expenses decreased to $8.8 million from $10.8 million. Net loss from continuing operations, net of tax, significantly narrowed to $22.6 million, or $0.21 per share, from $48.4 million, or $0.40 per share for the 2016 fourth quarter. Income from discontinued operations, net of tax, was $0.9 million, or $0.01 per diluted share, versus loss from discontinued operations, net of tax, $11.5 million, or $0.09 per share, for the prior-year fourth quarter. Net loss was $21.6 million, or $0.20 per share, compared with $60.0 million, or $0.49 per share, for 2016 fourth quarter.
Financial results for the 2017 fourth quarter included approximately $4.0 million loss from related party equity method investment, $0.7 million of acquisition related sales incentive, $1.2 million of net non-cash expense related to convertible notes, $2.2 million of intangible amortization and $8.6 million of stock-based compensation expense, totaling $0.16 per share. On a non-GAAP basis, adjusted net loss from continuing operations was $7.8 million, or $0.07 per share, for the 2017 fourth quarter, compared with $14.4 million, or $0.12 per share, for the 2016 fourth quarter.
For the 2017 full year, total net revenue increased 8% to $86.7 million from $80.4 million in 2016. Gross profit rose to $45.2 million, or 52% of total net revenue, compared with $36.3 million, or 45% of total net revenue, for the prior year. SG&A expenses were $75.0 compared with $105.3 million. R&D expenses decreased to $33.9 million from $47.3 million. Net loss from continuing operations, net of tax, was $131.4 million, or $1.12 per share, from $140.5 million, or $1.30 per share for 2016. Loss from discontinued operations, net of tax, was $43.8 million, or $0.37 per share, compared with $43.6 million, or $0.39 per share, for the prior year. Net loss was $175.2 million, or $1.49 per share, compared with $184.1 million, or $1.69 per share, for 2016.
Financial results for the 2017 full year included approximately $50.3 million loss from related party equity method investment including impairment loss, $2.4 million for corporate restructuring, $2.7 million of acquisition related sales incentive, $4.4 million of net non-cash expense related to convertible notes, $9.4 million of intangible amortization and $8.1 million of stock-based compensation expense, totaling $0.66 per share. On a non-GAAP basis, adjusted net loss from continuing operations was $55.3 million, or $0.47 per share, for the 2017 full year quarter, compared with $58.2 million, or $0.50 per share, for the 2016 full year.
Conference Call Information and Forward-Looking Statements
Later today, the company will host a conference call at 1:30 p.m. PT (4:30 p.m. ET) to review its results of operations for the fourth quarter and full year ended December 31, 2017. The conference call will be available to interested parties by dialing 844-309-3709 from the U.S. or Canada, or 281-962-4864 from international locations, passcode 2987414. The call will be broadcast via the Internet at www.nanthealth.com. Listeners are encouraged to visit the website at least 10 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software. A playback of the call will be archived and accessible on the same website for at least three months.
Discussion during the conference call may include forward-looking statements regarding topics such as the company’s financial status and performance, regulatory and operational developments, and other comments the company may make about its future plans or prospects in response to questions from participants on the conference call.
Use of Non-GAAP Financial Measures
This news release contains references to Non-GAAP financial measures, including adjusted net loss and adjusted net loss per share, which are financial measures that are not prepared in conformity with United States generally accepted accounting principles (U.S. GAAP). The Company’s management believes that the presentation of Non-GAAP financial measures provides useful supplementary information regarding operational performance, because it enhances an investor’s overall understanding of the financial results for the Company’s core business. Additionally, it provides a basis for the comparison of the financial results for the Company’s core business between current, past and future periods. Other companies may define these measures in different ways. Non-GAAP financial measures should be considered only as a supplement to, and not as a substitute for or as a superior measure to, financial measures prepared in accordance with U.S. GAAP. Non-GAAP per share numbers are calculated based on one class of common stock and do not incorporate the effects, if any, of using the two-class method.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth's unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissue and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system that integrates our unique molecular profiling solution, software and hardware. Our system infrastructure collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources to continuously improve decision-making and optimize our clinical pathways and decision algorithms over time. For more information please visit www.nanthealth.com.
About GPS Cancer™
GPS Cancer™ is a unique, comprehensive test available through
GPS Cancer integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics through mass spectrometry, providing oncologists with a comprehensive molecular profile of a patient’s cancer to inform personalized treatment strategies. GPS Cancer testing is conducted in CLIA-certified and CAP-accredited laboratories, and is a key enabler for Cancer Breakthroughs 2020, the world’s most comprehensive cancer collaborative initiative seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. For more information, visit www.gpscancer.com and www.cancerbreakthroughs2020.org.
This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our sequencing and molecular analysis solutions; establish relationships with, key thought leaders or payers’ key decision makers in order to establish GPS Cancer as a standard of care for patients with cancer; our ability to grow the market for our Systems Infrastructure, and applications; successfully enhancing our Systems Infrastructure and applications to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to continue our relationship with NantOmics; our ability to obtain regulatory approvals; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; clinical adoption and market acceptance of GPS Cancer; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.
|Consolidated Balance Sheets|
|(Dollars in thousands, except per share amounts)|
|Cash and cash equivalents||$||61,660||$||157,573|
|Accounts receivable, net||11,491||11,673|
|Deferred implementation costs||1,960||606|
|Related party receivables, net||585||693|
|Prepaid expenses and other current assets||5,358||3,356|
|Current assets of discontinued operations||-||9,992|
|Total current assets||81,893||185,578|
|Property, plant, and equipment, net||18,517||20,129|
|Deferred implementation costs, net of current||3,951||3,201|
|Intangible assets, net||69,424||78,812|
|Investment in related party||156,863||207,197|
|Related party receivable, net of current||1,727||1,971|
|Noncurrent assets of discontinued operations||-||70,683|
|Liabilities and Stockholders' Equity|
|Accrued and other current liabilities||18,134||20,032|
|Related party payables, net||4,504||8,082|
|Current liabilities of discontinued operations||-||13,496|
|Total current liabilities||35,859||57,249|
|Deferred revenue, net of current||7,126||11,127|
|Related party liabilities||11,500||5,612|
|Related party promissory note||112,666||112,666|
|Related party convertible note, net||7,947||7,564|
|Convertible notes, net||74,845||70,810|
|Noncurrent liabilities of discontinued operations||-||6,949|
|Common stock, $0.0001 par value per share, 750,000,000 shares authorized; 108,383,602 and 121,250,437 shares issued and outstanding at December 31, 2017 (including 3,490 shares of restricted stock) and 2016 (including 6,976 shares of restricted stock), respectively||10||12|
|Additional paid-in capital||886,669||886,334|
|Accumulated other comprehensive (loss) income||(144||)||521|
|Total stockholders' equity||193,302||411,594|
|Total liabilities and stockholders' equity||$||449,195||$||684,391|
Consolidated and Combined Statements of Operations
(Dollars in thousands, except per share amounts)
Three Months Ended
|Year Ended December 31,|
|Total net revenue||$||22,298||$||17,846||$||86,676||$||80,404|
|Total cost of revenue||8,880||10,893||41,522||44,107|
|Selling, general and administrative||20,795||16,398||74,976||105,258|
|Research and development||8,811||10,792||33,862||47,310|
|Amortization of acquisition-related assets||1,054||1,055||4,216||4,217|
|Total operating expenses||30,660||28,245||113,054||156,785|
|Loss from operations||(17,242||)||(21,292||)||(67,900||)||(120,488||)|
|Interest expense, net||(4,119||)||(1,669||)||(16,168||)||(6,429||)|
|Other income, net||492||3,052||800||3,593|
|Loss from related party equity method investment including impairment loss||(3,981||)||(33,101||)||(50,334||)||(40,994||)|
|Loss from continuing operations before income taxes||(24,850||)||(53,010||)||(133,602||)||(164,318||)|
|Provision for (benefit from) income taxes||(2,288||)||(4,594||)||(2,203||)||(23,797||)|
|Net loss from continuing operations||(22,562||)||(48,416||)||(131,399||)||(140,521||)|
|Loss from discontinued operations, net of tax||928||(11,535||)||(43,812||)||(43,581||)|
|Basic and diluted net income (loss) per share (1):|
|Continued operations - common stock||$||(0.21||)||$||(0.40||)||$||(1.12||)||$||(1.30||)|
|Discontinued operations - common stock||$||0.01||$||(0.09||)||$||(0.37||)||$||(0.39||)|
|Total net loss per common stock||$||(0.20||)||$||(0.49||)||$||(1.49||)||$||(1.69||)|
|Basic and diluted net income per redeemable common stock||N/A||N/A||N/A||$||0.99|
|Weighted average shares outstanding (1):|
|Basic and diluted - common stock||107,810,546||121,242,627||116,737,860||111,600,650|
|Basic and diluted - redeemable common stock||N/A||N/A||N/A||5,005,855|
The net income (loss) per share and weighted average shares outstanding have been computed to give effect to the LLC conversion that occurred on June 1, 2016, prior to the Company's initial public offering ("IPO"). In conjunction with the LLC conversion, (a) all of the Company's outstanding members' units automatically converted into shares of common stock, based on the relative rights of the Company's pre-IPO equity holders as set forth in the Company's limited liability company agreement and (b) the Company adopted and filed a certificate of incorporation with the Secretary of State of the state of Delaware and adopted bylaws. The Company adopted and filed an amendment to its certificate of incorporation with the Secretary of State of the state of Delaware to effect a 1-for-5.5 reverse stock split of its common stock on June 1, 2016.
The net loss per common share for the years ended December 31, 2016 reflects $4,958 in accretion value allocated to the redeemable common stock. The redeemable common stock contained a put right, which expired unexercised on June 20, 2016. As a result of and as of that date, the shares were no longer redeemable and were included in common stock.
|Supplemental Revenue Schedule|
|(Dollars in thousands)|
Three Months Ended
|Year Ended December 31,|
|Software and hardware||1,685||673||6,093||6,750|
Total software-related revenue
|Sequencing and molecular analysis||569||482||2,554||604|
|Total net revenue||$||22,298||$||17,846||$||86,676||$||80,404|
|Cost of Revenue:|
|Software and hardware||64||148||660||816|
|Total software-related cost of revenue||4,716||5,240||22,455||20,699|
|Sequencing and molecular analysis||1,222||1,058||6,029||1,987|
|Amortization of developed technologies||1,143||1,596||5,172||8,492|
|Total cost of revenue||$||8,880||$||10,893||$||41,522||$||44,107|
|Non-GAAP Net Loss and Non-GAAP Net Loss Per Share|
|(Dollars in thousands, except per share amounts)|
Three Months Ended
|Year Ended December 31,|
|Net loss from continuing operations||$||(22,562||)||$||(48,416||)||$||(131,399||)||$||(140,521||)|
|Adjustments to GAAP net loss:|
|Corporate restructuring from continuing operations (3)||17||246||2,422||2,544|
|Acquisition related compensation expense||-||-||-||4,814|
|Acquisition related sales incentive||671||939||2,732||2,966|
|Intangible amortization from continuing operations||2,197||2,651||9,388||12,709|
|Loss from related party equity method investment including impairment loss||3,981||33,101||50,334||40,994|
|Non-cash interest expense related to convertible notes||1,157||108||4,417||108|
|Change in fair value of derivatives liability||(19||)||(1,228||)||(264||)||(1,228||)|
|Stock-based compensation expense from continuing operations||8,586||3,599||8,102||44,048|
|Securities litigation costs||92||-||777||-|
|The impact of intangible amortization, impact of the "Tax Act" of 2017, and the conversion from a limited liability company to a corporation on provision for (benefit from) income taxes||(1,909||)||(4,509||)||(1,796||)||(23,797||)|
|Total adjustments to GAAP net loss from continuing operations||14,773||34,065||76,112||82,316|
|Net loss - Non-GAAP from continuing operations||$||(7,789||)||$||(14,351||)||$||(55,287||)||$||(58,205||)|
|Weighted average shares outstanding (1)||107,810,546||121,242,627||116,737,860||111,600,650|
|Weighted average Series F/redeemable stock (1) (2)||—||—||—||5,005,855|
|Shares outstanding - Non-GAAP (1)||107,810,546||121,242,627||116,737,860||116,606,505|
|Net loss per share from continuing operations - Non-GAAP (1)||$||(0.07||)||$||(0.12||)||$||(0.47||)||$||(0.50||)|
Reconciliation of Net Loss per Common Share to Net Loss per Common Share - Non-GAAP:
Three Months Ended
|Year Ended December 31,|
|Net loss per common share from continuing operations - GAAP||$||(0.21||)||$||(0.40||)||$||(1.12||)||$||(1.30||)|
|Adjustments to GAAP net loss per common share from continuing operations:|
|Corporate restructuring from continuing operations (3)||—||—||0.02||0.02|
|Acquisition related compensation expense||—||—||—||0.04|
|Acquisition related sales incentive||0.01||0.01||0.02||0.03|
|Intangible amortization from continuing operations||0.02||0.03||0.08||0.12|
|Loss from related party equity method investment including impairment loss||0.04||0.27||0.43||0.37|
|Non-cash interest expense related to convertible notes||0.01||—||0.04||—|
|Change in fair value of derivatives liability||—||(0.01||)||—||(0.01||)|
|Stock-based compensation expense from continuing operations||0.08||0.03||0.07||0.39|
|Securities litigation costs||—||—||0.01||—|
|The impact of intangible amortization, impact of the "Tax Act" of 2017, and the conversion from a limited liability company to a corporation on provision for (benefit from) income taxes||(0.02||)||(0.04||)||(0.02||)||(0.21||)|
|Accretion to redemption value of Series F/redeemable common stock||—||—||—||0.04|
|Dilution from Series F/redeemable common stock||—||—||—||0.02|
|Total adjustments to GAAP net loss per common share from continuing operations||0.14||0.28||0.65||0.80|
|Net loss per common share from continuing operations - Non-GAAP (1)||$||(0.07||)||$||(0.12||)||$||(0.47||)||$||(0.50||)|
|(1)||The net loss per common share from continuing operations - non-GAAP, weighted-average shares outstanding, weighted average Series F units/redeemable stock and shares outstanding - non-GAAP, have been computed to give effect to the LLC conversion that occurred June 1, 2016 prior to our initial public offering. In conjunction with the LLC Conversion, (a) all of our outstanding units automatically converted into shares of common stock, based on the relative rights of our pre-IPO equityholders as set forth in the limited liability company agreement and (b) we adopted and filed a certificate of incorporation with the Secretary of State of the state of Delaware and adopted bylaws. We filed an amended certificate of incorporation to effect a 1-for-5.5 reverse stock split of our common stock on June 1, 2016.|
|(2)||The weighted-average shares outstanding have been further adjusted to account for the redeemable Series F units (converted to common stock in conjunction with the LLC conversion), whose put right expired on June 20, 2016. Prior to June 20, 2016, these units/shares of common stock were classified as redeemable members’/stockholders’ equity in the balance sheet, and as such, were not included in the weighted-average shares outstanding prior to June 20, 2016. The put right expired June 20, 2016, and the shares were no longer redeemable and are included in shareholders’ equity as of December 31, 2016. The weighted-average shares are adjusted to include the redeemable common stock in the weighted-average shares outstanding for the entire period.|
|(3)||Corporate restructuring includes accrued bonus reversal of $0.5 million for the year ended December 31, 2017.|